

Improving Global Outcomes in Patients with Hepatitis C and Chronic Kidney Disease

Authors

Ahmed A. Awan, MD¹, Michel Jadoul, MD², Paul Martin, MD³

Affiliations

¹ Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA

² Cliniques Universitaires Saint Luc, Université catholique de Louvain, Brussels, Belgium

³ Miller School of Medicine, University of Miami, Miami, FL, USA

Conflict of Interest:

Ahmed Awan

Disclosures: No conflicts of interest

Michel Jadoul

Disclosures: Research Grant: Merck Sharp and Dohme (MSD); Speaker Honoraria: Abbvie (2017) and MSD (2017-18); Consultant; MSD (2017-18)

Paul Martin

Disclosures: Investigator/Consultant: Abbvie, Gilead, and Merck

Contribution of Authors:

All authors equally contributed to the conception, drafting and critical revision of the article. All authors have approved the final version to be published.

Abstract

Hepatitis C viral (HCV) infection is a global health problem with significant health and economic burden, which can lead to chronic kidney disease (CKD) and affect multiple organ systems. In addition, prevalence of hepatitis C remains higher in patients with CKD, including those on chronic hemodialysis and in individuals with a kidney transplant than in the general population. There has been a dramatic shift in the management of hepatitis C since Kidney Disease: Improving Global Outcome (KDIGO) published its 2008 guideline for the prevention, diagnosis and management of hepatitis C in CKD. As a result, KDIGO published in 2018 an update to this guideline. In this narrative review, we present a synopsis of the guideline, including recommendations for screening and detection of HCV in CKD, treatment of HCV in patients with CKD, treatment of HCV before and after kidney transplantation, prevention of HCV transmission in hemodialysis units, and treatment of kidney disease related to HCV infection. We focus on the clinical aspects of using direct acting antivirals (DAAs) in patients with advanced CKD (G4 and G5), those on dialysis and kidney transplant recipients. We emphasize the importance of carefully managing drug-drug interactions between DAAs and immunosuppressive agents. We discuss timing of HCV treatment before vs. after kidney transplantation. Finally, we highlight areas of uncertainty where further research is needed before any definitive recommendations can be made.

Introduction

The World Health Organization (WHO) has called for elimination of viral hepatitis as a public health threat by reducing new infections by 90% and mortality by 65% by 2030.¹ Unlike other communicable diseases, the global burden and relative rank of viral hepatitis increased from 1990 (0.89 million deaths per year) to 2013 (1.45 million deaths per year).² Hepatitis B and C cause 96% of mortality related to viral hepatitis. While deaths from hepatitis B Virus (HBV) have plateaued since 1990 after introduction of HBV vaccination, deaths from hepatitis C Virus (HCV) continue to rise.³ HCV remains the most common chronic blood-borne infection worldwide, affecting an estimated 71 million people in 2015.⁴ It leads to significant morbidity and mortality due to its hepatic and extra-hepatic effects, representing an immense health and economic burden.⁵

Chronic kidney disease (CKD) is defined by Kidney Disease: Improving Global Outcomes (KDIGO) as “abnormalities of kidney structure and function, present for > 3 months, with implications for health”,⁶ and is classified based on cause, GFR category (G1-G5) and albuminuria category (A1-3), as shown in Figure 1. The current definition of CKD modifies previous classification⁷ by emphasizing the cause of kidney disease, adding albuminuria category, and subdividing GFR category 3 in 3a and 3b. CKD has an estimated worldwide prevalence of 8-16%.⁸ According to USRDS annual data report, CKD prevalence in the US adult general population was 14.8% from 2013-2016 and has been stable over the last two decades.⁹

Reflecting the complex relationship between HCV infection and CKD, KDIGO has recently published an updated guideline incorporating advances in the prevention, diagnosis, evaluation, and treatment of HCV in this population which we highlight here.

Detection and evaluation of HCV in CKD

Relationship between HCV and CKD

The prevalence of HCV infection in patients undergoing hemodialysis remains higher than in general population,^{10,11} despite a decrease over the last 2 decades.¹² Using Dialysis Outcomes and Practice Patterns Study (DOPPS), Jadoul et al. reported that in hemodialysis patients, HCV infection defined by a documented diagnosis or antibody seropositivity was present in nearly 10% in 2012-2015. Prevalence ranged from 4% in Belgium to as high as 20% in the Middle East, with intermediate prevalence in China, Japan, Italy, Spain, and Russia.¹³ HCV prevalence in US units decreased from 11.5% to 6.9% over 1996-2015 study period. However, given that there were 448,000 patients on hemodialysis in US by the end of 2016,⁹ this implies that 31000 of these are seropositive for HCV. Mechanisms of HCV acquisition among hemodialysis patients include typical HCV risk factors (e.g. intravenous drug use, remote blood transfusions etc.) as well as risk of nosocomial transmission during hemodialysis. HCV infection in hemodialysis patients is implicated in diminished quality of life scores and higher risk of hospitalization and mortality.¹⁴ An estimated 4.8% of transplant-waitlisted hemodialysis patients are seropositive for hepatitis C.¹⁵ Interestingly, the recent DOPPS study also looked at prevalence of HCV positivity at start of hemodialysis (thus HCV was acquired prior to hemodialysis) , and found a prevalence of ~ 5% - a figure that hardly changed over the last 2 decades, and is much higher than in the general population in the DOPPS countries.¹³ The prevalence of HCV infection among kidney transplant recipients (KTRs) is nearly 5% in Western countries¹⁶, although in France it was lower at 1.4%.¹²

Conversely, HCV infection increases the risk of CKD development and progression.^{17,18} Renal deposition of immune complexes (which may or may not be cryoprecipitable) is the main mechanism of glomerular inflammation caused by HCV infection. Pre-existing comorbidities (e.g. hypertension, diabetes and cardiovascular disease) enhance the rate of progression of CKD to end-stage kidney disease (ESKD) in HCV positive patients.¹⁹⁻²² HIV-infected patients who are HCV seropositive have an increased likelihood of a diminished GFR, compared to patients with HIV-infection alone.²³ In a

retrospective cohort analysis, HCV-positive patients had a 2-fold higher risk of membranoproliferative glomerulonephritis (MPGN) and a 17-fold higher risk of cryoglobulinemia.¹⁸ A direct cytopathic effect of HCV on the kidney is also suspected.²⁴

Screening for HCV in CKD and evaluation of liver involvement

All patients with CKD, including those initiating kidney replacement therapy (hemodialysis, peritoneal dialysis or transplant evaluation), should undergo screening for HCV. One-time screening needs to be performed by the physician who initially diagnoses CKD, regardless of GFR. Detection of anti-HCV antibody by screening immunoassays (enzyme or chemoluminescence) with infection confirmed by nucleic acid testing (NAT) is required to make a diagnosis. In a recent study of 201 hemodialysis patients in Vietnam, the positive predictive value of anti-HCV antibody for HCV viremia was 73%, while the negative predictive value was 90%. In other words, HCV-RNA was positive in 10% of anti-HCV negative patients.²⁵ This figure largely results from the window period (delay between viremia after contamination, and seroconversion (and thus EIA positivity)). Thus, in hemodialysis units with a high prevalence of HCV, initial testing with NAT should be considered. NAT samples should be drawn before dialysis, as hemodialysis reduces viremia level. However, this reduction in HCV RNA is not dependent on dialysis schedule or type of membrane used.²⁶

Qualitative and quantitative methods are available to confirm HCV viremia with a lower limit of detection of 10-20 [IU]/ml). HCV antigen tests using core antigens or other protein components have a higher limit of detection (150-3000 [IU]/ml) and are not commonly used, despite being less expensive. Serum alanine aminotransferase (ALT) monitoring is an inexpensive way of surveillance for HCV acquisition between regular antibody or NAT testing. Therefore, a baseline serum ALT level, followed by monthly testing, is recommended for patients who initiate in-center hemodialysis or get transferred from another facility. In a prospective study of 2440 hemodialysis patients, a newly elevated ALT level had a sensitivity of 83% and a specificity of 90% for acute HCV infection.²⁷ Beyond the acute phase, ALT level

is generally within normal limits in HCV-positive dialysis patients, even though slightly higher in HCV-positive than HCV-negative patients.²⁸

Noninvasive methods (elastography, aspartate aminotransferase platelet ratio index [APRI], Fibrotest/Fibrometer, FIB4 index) are recommended as initial tests for staging liver fibrosis. Transient elastography (Fibroscan[®]) measures the velocity of low-frequency elastic shear wave propagation through the liver. This velocity is directly related to tissue stiffness. In a study of 284 Taiwanese hemodialysis patients with chronic HCV, transient elastography was superior to APRI in detecting advanced hepatic fibrosis and cirrhosis (Metavir stage F3 and F4).²⁹ Non-invasive screening tests have a high negative predictive value,³⁰ but may be false-positive in obese patients, or patients with fluid overload. Nowadays, liver biopsy can be reserved for patients with equivocal non-invasive testing or if an additional diagnosis is possible, such as iron overload.

If cirrhosis is suspected or confirmed, the severity of portal hypertension needs to be determined. Upper endoscopy is indicated to screen for esophageal varices. Clinically significant portal hypertension (hepatic-vein wedge-pressure gradient ≥ 10 mmHg) is unusual in patients with cirrhosis if elastography is < 20 kPa and platelet count is $> 150,000/\text{mm}^3$,³¹ and invasive measurement of portal hypertension is only required in the absence of these findings.

Preventing HCV transmission in hemodialysis units

Measures to prevent HCV transmission in HD units are well recognized.^{32,33} In most reported HCV outbreaks in hemodialysis centers, multiple deficiencies in infection control are typically identified, including lapses in hand hygiene and glove use, injectable medication handling, and environmental surface disinfection. Regular assessment and adherence to evidence-based interventions should be reinforced through observational audits. Guidelines do not recommend isolating HCV-infected patients during hemodialysis sessions. Similarly, use of dedicated dialysis machines for these patients is not

recommended as there is no evidence to suggest HCV transmission through internal pathways of single-pass dialysis machines.

Patients in hemodialysis units should be screened for HCV-infection using ALT level monthly and HCV immunoassay or NAT every 6 months. If a newly acquired HCV-infection is detected, all patients in the hemodialysis center should be tested and frequency of subsequent testing should be increased as well as a detailed review of infection control practices must be conducted. Lastly, seroconversion for HCV suspected to have been acquired on HD should be reported to public health authorities.

Treatment for HCV infection in patients with CKD

Benefits of treatment

Multiple studies have found an association between sustained viral response (SVR) and reduction in mortality in the general population.³⁴ In addition to the renal benefits of achieving SVR with treatment of HCV in CKD patients, additional benefits may include mitigating other extra-hepatic manifestations, with reduction in vascular events³⁵, and improvement in cryoglobulinemic vasculitis.³⁶ SVR reduces the risk of deterioration in kidney function and ESKD-related mortality compared to that of untreated patients. In a recent study of 204 liver transplant recipients with HCV, achieving a SVR was associated with 88% lower risk of CKD and 86% lower risk of ESKD (in unadjusted cox-proportional regression analysis).³⁷

Therapeutic options

In addition to low efficacy, interferon-based therapy had limited use in the CKD population due to poor tolerability and concern about graft rejection in kidney transplant recipients. In addition, ribavirin use in the CKD population is limited by its propensity to cause severe anemia.

NS3/4A protease inhibitors were the first DAAs approved in 2011 and since then, numerous DAAs have been licensed. NS5A replication complex inhibitors and non-nucleoside NS5B polymerase inhibitors do not require dose adjustments in advanced stages of CKD and can be used in CKD G4-G5. Sofosbuvir is not recommended for patients with eGFR less than 30 ml/min/1.73 m².

All treatment candidates should undergo assessment for HBV infection prior to therapy, and if hepatitis B surface antigen [HBsAg] is detected, antiviral therapy for HBV should be considered to prevent HBV reactivation as a consequence of DAA therapy. If initial HBV testing is negative, but there is evidence of prior resolved infection (e.g. positive antibody to HBV core antigen [HBcAb]), patients should be monitored for HBV reactivation during DAA therapy using serial HBV DNA and liver function tests.

Who should be treated?

Given the significant liver, cardiovascular and kidney benefits of achieving SVR in CKD patients with HCV infection, guideline recommends that all infected patients should be considered for treatment.

Treatment of HCV in patients with CKD (G1-G5 and G5D)

Algorithm 1 shows treatment options for HCV-infected patients with CKD. The joint recommendations from American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) can be accessed at hcvguidelines.org.³⁸ For patients with *CKD G1-G3b* (eGFR > 30ml/min/1.73m²), KDIGO³⁹ and EASL⁴⁰ recommend using any one of the available DAAs based on viral load, HCV genotype, degree of fibrosis and treatment history. No dose modification is necessary for most combination drug regimens. Velpatasvir, however, has not been approved for use in CKD G1-G3b in some jurisdictions. Sofosbuvir is predominantly renally cleared (80%) and is approved for use only in individuals with eGFR > 30 ml/min/1.73 m². These patients typically receive a combination of sofosbuvir-velpatasvir, ledipasvir-sofosbuvir, glecaprevir-pibrentasvir, or grazoprevir-elbasvir. Use of protease-inhibitors is contraindicated in patients with cirrhosis due to reports of hepatic decompensation with these agents.

In *CKD G4-G5, including patients on dialysis (G5D)*, a low eGFR, in addition to viral genotype, is the major determinant in choice of DAAs. A regimen combining elbasvir and grazoprevir has been studied in advanced CKD and is recommended for use in HCV genotypes (GTs) 1 and 4. In the C-SURFER trial, HCV GT1-infected patients with CKD G4-G5 were treated with a combination of elbasvir and

grazoprevir for 12 weeks. Both drugs are metabolized by CYP3A4 and are primarily (> 90%) excreted in feces with <1% renal elimination, making dose adjustment unnecessary. SVR was 99% with excellent tolerability. Change in eGFR and need to initiate hemodialysis was similar in intervention and control groups.^{41,42} Co-administration with CYP3A4 inducers (such as rifampin, phenytoin, St. John's wart) is contraindicated as it may reduce antiviral activity of both agents. Co-administration with drugs that inhibit OATP1B1/3 (enalapril, statins, digoxin, some angiotensin-receptor blockers) may increase levels of grazoprevir and cause hyperbilirubinemia. Similar to other protease-inhibitors, grazoprevir cannot be used in patients with Child-Turcotte-Pugh class B and C cirrhosis due to risk of hepatotoxicity. Caution is advised when using concomitantly with drugs that are extensively metabolized in liver and have narrow therapeutic index, e.g. cyclosporine. Viral eradication may improve hepatic metabolic function, thus leading to decreased levels and efficacy of such drugs.

Pangenotypic glecaprevir-pibrentasvir combination is an option for the treatment of HCV in CKD G4-G5D patients, regardless of genotype. It can be used in patients with cirrhosis and those who failed treatment with IFN-based therapies. In the EXPEDITION-4 study, the glecaprevir-pibrentasvir regimen was used for 12 weeks to treat HCV GTs 1-6 in patients with CKD G4-G5 and achieved SVR of 98% (102 out of 104 patients).⁴³ The majority (82%) of patients were on hemodialysis and 42% had been treated previously, including 2 with sofosbuvir-based therapy. In an integrated analysis of 9 trials with 2,041 patients without cirrhosis, treatment with glecaprevir-pibrentasvir for 8-weeks achieved a similar SVR (98%) and was efficacious regardless of baseline kidney function.⁴⁴ As these drugs are highly protein bound, timing of administration does not need to be altered even on dialysis days.

RUBY-II enrolled patients with CKD G4-G5D with HCV GT1a and 4 infection and treated them with ritonavir-boosted paritaprevir and ombitasvir (plus dasabuvir in GT1a patients- "PrOD regimen") for 12 weeks. Of the 18 treated patients, 17 achieved SVR and the remaining one patient elected to undergo kidney transplantation.⁴⁵ Trials of DAAs in patients with advanced CKD are summarized in Table 1.

Screening for hepatocellular carcinoma is recommended for cirrhotic patients after achieving SVR, and may also be considered for patients with stage 3 fibrosis.

Treatment of HCV in kidney transplant recipients (KTRs)

Although published data in KTRs is less abundant, results are as satisfactory as in liver transplant recipients. KTRs, even with well-functioning grafts, have baseline CKD (due to various immunologic and non-immunologic mechanisms) which is classified as G1T to G5T. Similar to patients with CKD, KTRs with a GFR > 30 ml/min/1.73 m² (CKD G1T-G3bT) and HCV GTs 1 and 4 can be treated with either a sofosbuvir-based regimen or pibrentasvir-glecaprevir. For GTs 2,3,5 and 6, pibrentasvir-glecaprevir is recommended. If eGFR is < 30 ml/min/1.73m², the same regimens are recommended as used for CKD G4-G5D.

Interferon-free regimens are recommended for KTRs. DAAs, including sofosbuvir-based regimens, are well-tolerated and effective, but do require dose-adjustment of immunosuppressive medications in more than half of KTRs.⁴⁶ Ledipasvir-sofosbuvir use in 114 KTRs with eGFR > 40 ml/min/1.73m² for 12 or 24 weeks showed 100% SVR regardless of treatment duration. Serious adverse events occurred in 11% , with 3 patients experiencing an increase in creatinine.⁴⁷ MAGELLAN-2 was a phase-3 open-label trial that used glecaprevir-pibrentasvir for 12 weeks in 80 liver and 20 kidney transplant recipients infected with HCV GTs 1-6 and reported SVR of 98%. There was one virologic failure and one patient dropped out due to adverse events.⁴⁸

Drug-drug interactions are an important consideration in KTRs and DAAs can lead to elevated or suppressed levels of immunosuppressive medications, resulting in graft rejection or toxicity.

Cyclosporine, tacrolimus, everolimus and sirolimus are metabolized by cytochrome P450. Protease-inhibitors are associated with a significant risk of interaction with calcineurin inhibitors (CNIs) or mTOR inhibitors, whereas NS5A inhibitors (ledipasvir, daclatasvir) and NS5B inhibitors (sofosbuvir) are associated with a lower risk of interaction with these agents. Concurrent use of elbasvir-grazoprevir with

cyclosporine is not recommended as it increases AUC for grazoprevir by 15-fold and elbasvir by 2-fold. Elbasvir-grazoprevir results in an increase in tacrolimus level by 43%, so level needs to be closely monitored. Other protease inhibitors, like simeprevir and paritaprevir, have similar interactions. Protease inhibitors do not interact with mycophenolate mofetil (MMF). Drug-drug interactions should be checked using a reliable source prior to initiating therapy, such as The University of Liverpool website⁴⁹.

Management of patients with HCV before and after kidney transplantation

Algorithm 2 depicts management options for HCV in kidney transplant candidates.

HCV-positive recipient

Kidney transplantation remains the best treatment option for patients with ESKD due to a significant survival advantage,^{50,51} regardless of HCV status. Although patient and graft survival is inferior in patients with persistent HCV replication after transplant compared to HCV negative recipients,⁵² patient survival is better compared to remaining on dialysis.⁵³ HCV-infected patients with decompensated cirrhosis should be evaluated for combined liver-kidney transplantation.

Since the advent of DAAs, HCV infection in potential KTRs can be treated before or after kidney transplantation. Timing of HCV treatment depends on donor-type, wait-list times, center-specific policies regarding the use HCV-infected deceased donors, HCV genotype and severity of liver fibrosis. If a living kidney transplantation is anticipated without a long wait, HCV treatment can be deferred until after transplantation. However, wait-times longer than 24 weeks allow sufficient time for treatment (12 weeks) and confirmation of SVR (12 weeks).

For deceased donors, KDIGO strongly recommends that kidneys from HCV NAT-positive donors should be directed to recipients with positive NAT.³⁹ Thus, if acceptance of a graft from an HCV-positive donor reduces the wait-time for transplantation, a patient can undergo transplantation with an HCV-positive kidney and get treatment for HCV-infection after transplant. The patient needs to provide informed consent for this approach. In a multi-center study, this strategy didn't adversely affect patient or graft

survival.⁵⁴ Waitlist times vary according to the region but are typically shorter for recipients of HCV-positive organs. Treatment of HCV in KTRs can be initiated once patient is on a stable immunosuppression regimen. Deferred-treatment may not be suitable for patients with more advanced liver fibrosis. However, with the availability of DAAs, compensated cirrhosis is no longer a contraindication for an isolated kidney graft, as DAA therapy will halt and eventually, to some extent, even reverse the liver disease. Also, due to potential for drug-drug interactions with immunosuppressive medications, unpredictable timing of kidney transplantation, and poor prognosis of patients with HCV and CKD, many clinicians are inclined towards treating these patients as soon as possible.

HCV-positive donor

HCV NAT-positive living donors should be treated and SVR should be confirmed prior to transplantation, as long as they meet other criteria for a suitable living donor and have no evidence of cirrhosis. In the US, almost 100,000 patients are waitlisted for kidney transplantation each year⁵⁵ and waiting times exceed 3-5 years.⁵⁶ Despite the substantial need for organs, more than 800 kidneys from HCV-infected donors were discarded in 2016.⁵⁶ Overall 4.2% of organs are offered from HCV positive donors.⁵⁷ If a donor is anti-HCV positive but NAT-negative, the kidney can be safely transplanted into an HCV-negative recipient.⁵⁷ Results of kidney transplantation from HCV NAT-positive donor to HCV-positive recipients who were treated with DAAs following transplantation are also reassuring.⁵⁸ However, whether these kidneys can be routinely transplanted in HCV-negative recipients is still under investigation. An analysis of US Organ Procurement and Transplantation Network (OPTN) database through 2012 showed inferior outcomes in HCV-negative recipients who received HCV-positive kidneys⁵⁹ and this practice was considered unacceptable. However, the availability of DAAs has led clinicians to reconsider this. In the THINKER-1 trial, all of the 10 HCV-negative patients who received HCV-positive kidneys followed by DAA treatment achieved HCV cure and excellent kidney function.⁶⁰ In EXPANDER-1, 8 HCV-negative patients were transplanted with HCV-positive kidneys and were treated with one dose of grazoprevir/elbasvir pre-transplant and then daily for 12 weeks post-transplant.

HCV RNA was detected in 4 patients on postoperative day 1 but was not detected later-on. HCV RNA was never detected in the other 4 recipients.⁶¹ However, until more data is available, this approach is considered investigational.

Choice of immunosuppression

As immunosuppression facilitates viral replication, viral load increases after transplantation and there is increased risk of death from infection in the first 6 months after transplantation.⁶² The increased risk of death from antibody induction drops after the first 6 months⁶² and studies have suggested that antibody induction has no detrimental effect on long-term survival in HCV-positive patients.⁶³ Steroid-sparing regimens may reduce the risk of post-transplant diabetes⁶⁴ but there is no effect on mortality.⁶³ Tacrolimus also increases the risk of diabetes⁶⁵ and MMF has shown to increase serum HCV RNA concentration.⁶⁶ However, both these drugs are backbone of current immunosuppression protocols and MMF can be used regardless of HCV status.⁶² No single induction or maintenance immunosuppression medication is contraindicated in KTRs with HCV.

Follow-up

HCV-infected KTRs who are treated before transplantation and achieve SVR should be tested by NAT 3-months after transplantation. HCV-infected KTRs should be tested for proteinuria every 6-months and development of proteinuria (urine protein to creatinine ratio > 1g/g or 24-hour urine protein > 1g on 2 occasions) should trigger a kidney biopsy.

Diagnosis and management of kidney diseases associated with HCV infection

Although chronic HCV can cause tubulointerstitial injury,⁶⁷ the most frequent form of renal involvement is membranoproliferative glomerulonephritis (MPGN), often due to cryoglobulinemic vasculitis. MPGN can also present in the absence of cryoglobulinemia.^{68,69} Membranous nephropathy is another less frequent histologic pattern in patients with HCV infection.⁷⁰ Clinical manifestations include proteinuria, microscopic hematuria, hypertension, acute nephritic and nephrotic syndrome. Kidney biopsy can

establish a precise diagnosis and exclude other etiologies such as diabetic nephropathy, not infrequent in HCV patients.⁷¹ Patients with HCV-associated glomerular disease with stable kidney function and non-nephrotic range proteinuria should initially be treated with DAAs as this can result in remission of hematuria, proteinuria with improvement in eGFR.⁷² In patients with rapidly progressive kidney failure, acute cryoglobulinemic flare or nephrotic syndrome, immunosuppression (using rituximab as first-line agent) with or without plasma exchange should be considered before initiating DAAs. The superiority of rituximab over conventional immunosuppressants in cryoglobulinemic vasculitis was established in two randomized trials,^{73,74} but these trials included a minority of patients with renal involvement. In a recent prospective study with 6-year follow-up, rituximab use in 16 patients with diffuse MPGN was associated with an improvement in nephropathy starting the second month after rituximab administration.⁷⁵ Rituximab can lead to reactivation of HBV, and a black box warning on rituximab label has been added by FDA.⁷⁶

Areas of uncertainty

The role of DAAs in preventing and slowing the progression of CKD in the HCV infected population is not clear and needs to be evaluated. Optimal timing of antiviral therapy before or after kidney transplantation in kidney transplant candidates needs to be clarified and use of HCV-positive donors for HCV-negative recipients (with DAAs) needs to be explored further. Additional studies are required to understand how meticulous attention to body fluid precautions can be improved further to prevent HCV transmission within hemodialysis units, thus obviating the need for isolation or dedicated dialysis machines for HCV-infected patients.

Conclusion

Significant strides have been made in the treatment of HCV-infection since the availability of DAAs. Especially, pangenotypic medications that can be used even in patients with advanced CKD have made HCV cure a realistic goal. However, financial concerns⁷⁷ and lack of referral to hepatologists⁷⁸ for

treatment remain significant obstacles towards complete elimination of HCV. Promoting access to DAAs⁷⁹ and reducing risk of HCV-transmission in dialysis centers, along with universal immunization for HBV, can make it possible to eliminate viral hepatitis within the next decade as a global health problem.⁸⁰

REFERENCES

1. WHO. Draft global health sector strategy on viral hepatitis, 2016-2021 - the first of its kind 2015; https://www.who.int/hepatitis/strategy2016-2021/Draft_global_health_sector_strategy_viral_hepatitis_13nov.pdf. Accessed 2/3/2019.
2. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. *Lancet*. 2016;388(10049):1081-1088.
3. WHO. Global Hepatitis Report 2017. <https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/>. Accessed 2/4/2019.
4. Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol*. 2017;2(3):161-176.
5. Younossi Z, Brown A, Buti M, et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. *J Viral Hepat*. 2016;23(3):217-226.
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*. 2013; 3: 1–150.
7. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2005;67(6):2089-2100.
8. Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. *Kidney Int*. 2015;88(5):950-957.
9. United States Renal Data System : Annual Data Report 2018 https://www.usrds.org/2018/view/v1_01.aspx. Accessed February 26, 2019.
10. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. *Kidney Int*. 2004;65(6):2335-2342.
11. Saune K, Kamar N, Miedouge M, et al. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. *Nephrol Dial Transplant*. 2011;26(7):2309-2316.
12. Isnard Bagnis C, Couchoud C, Bowens M, et al. Epidemiology update for hepatitis C virus and hepatitis B virus in end-stage renal disease in France. *Liver Int*. 2017;37(6):820-826.
13. Jadoul M, Bieber BA, Martin P, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. *Kidney Int*. 2019;95(4):939-947.
14. Goodkin DA, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni RL. Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis. *Clin J Am Soc Nephrol*. 2017;12(2):287-297.
15. Goodkin DA, Bieber B. International prevalence of hepatitis C positivity among hemodialysis patients awaiting transplantation. *Kidney Int*. 2018;93(5):1249.
16. Baid-Agrawal S, Schindler R, Reinke P, et al. Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. *J Hepatol*. 2014;60(5):928-933.
17. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis. *Dig Dis Sci*. 2015;60(12):3801-3813.
18. Park H, Chen C, Wang W, Henry L, Cook RL, Nelson DR. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. *Hepatology*. 2017.
19. Petta S, Macaluso FS, Craxi A. Cardiovascular diseases and HCV infection: a simple association or more? *Gut*. 2014;63(3):369-375.

20. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? *J Viral Hepat.* 2012;19(9):601-607.
21. Crook ED, Penumalee S, Gavini B, Filippova K. Hepatitis C is a predictor of poorer renal survival in diabetic patients. *Diabetes Care.* 2005;28(9):2187-2191.
22. Soma J, Saito T, Taguma Y, et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. *J Am Soc Nephrol.* 2000;11(4):690-699.
23. Fabrizi F, Dixit V, Martin P, Messa P. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and meta-analysis. *J Med Virol.* 2016;88(3):487-497.
24. Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. *Nat Rev Nephrol.* 2019;15(2):73-86.
25. Duong MC, McLaws ML. Screening haemodialysis patients for hepatitis C in Vietnam: The inconsistency between common hepatitis C virus serological and virological tests. *J Viral Hepat.* 2019;26(1):25-29.
26. Barril G, Bartolome J, Sanz P, et al. Effect of hemodialysis schedules and membranes on hepatocyte growth factor and hepatitis C virus RNA levels. *J Med Virol.* 2010;82(5):763-767.
27. Saab S, Martin P, Brezina M, Gitnick G, Yee HF, Jr. Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysis. *Am J Kidney Dis.* 2001;37(2):308-315.
28. Fabrizi F, Lunghi G, Raffaele L, et al. Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs. *Nephrol Dial Transplant.* 1997;12(2):298-303.
29. Liu CH, Liang CC, Huang KW, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. *Clin J Am Soc Nephrol.* 2011;6(5):1057-1065.
30. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol.* 2009;7(10):1104-1112.
31. de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *J Hepatol.* 2015;63(3):743-752.
32. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. *Kidney Int.* 1998;53(4):1022-1025.
33. Jadoul M. Transmission routes of HCV infection in dialysis. *Nephrol Dial Transplant.* 1996;11 Suppl 4:36-38.
34. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. *Clin Infect Dis.* 2016;62(6):683-694.
35. Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. *Gut.* 2018;67(11):2025-2034.
36. Agnello V, Mecucci C, Casato M. Regression of splenic lymphoma after treatment of hepatitis C virus infection. *N Engl J Med.* 2002;347(26):2168-2170; author reply 2168-2170.
37. Satapathy SK, Joglekar K, Molnar MZ, et al. Achieving Sustained Virological Response in Liver Transplant Recipients With Hepatitis C Decreases Risk of Decline in Renal Function. *Liver Transpl.* 2018;24(8):1040-1049.
38. AASLD, IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. 2019; <https://www.hcvguidelines.org/>. Accessed 3/30/2019.
39. Kidney Disease: Improving Global Outcomes Hepatitis CWG. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. *Kidney Int Suppl (2011).* 2018;8(3):91-165.
40. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Recommendations on Treatment of Hepatitis C 2018. *J Hepatol.* 2018;69(2):461-511.

41. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. *Lancet*. 2015;386(10003):1537-1545.
42. Bruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. *Lancet Gastroenterol Hepatol*. 2017;2(8):585-594.
43. Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. *N Engl J Med*. 2017;377(15):1448-1455.
44. Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. *J Hepatol*. 2018;69(2):293-300.
45. Lawitz E, Gane E, Cohen E, et al. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. *Kidney Int Rep*. 2019;4(2):257-266.
46. Sawinski D, Kaur N, Ajeti A, et al. Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents. *Am J Transplant*. 2016;16(5):1588-1595.
47. Colombo M, Aghemo A, Liu H, et al. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. *Ann Intern Med*. 2017;166(2):109-117.
48. Reau N, Kwo PY, Rhee S, et al. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. *Hepatology*. 2018;68(4):1298-1307.
49. HEP Drug Interactions. <https://www.hep-druginteractions.org>.
50. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. *JAMA*. 1993;270(11):1339-1343.
51. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. *N Engl J Med*. 1999;341(23):1725-1730.
52. Scott DR, Wong JK, Spicer TS, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. *Transplantation*. 2010;90(11):1165-1171.
53. Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. *Am J Transplant*. 2005;5(1):139-144.
54. Chascsa DM, Mousa OY, Pungpapong S, et al. Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study. *Am J Transplant*. 2018;18(10):2559-2565.
55. Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2016 Annual Data Report: Kidney. *Am J Transplant*. 2018;18 Suppl 1:18-113.
56. U.S. Department Of Health & Human Services : Organ Procurement & Transplantation Network 2019; <https://optn.transplant.hrsa.gov>. Accessed February 25, 2019.
57. Nowak KM, Witzke O, Sotiropoulos GC, et al. Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome. *Kidney Int Rep*. 2017;2(1):53-59.
58. Gupta G, Kang L, Yu JW, et al. Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data. *Clin Transplant*. 2017;31(10).
59. Limkemann A, Ramanathan R, Behnke M, et al. Inferior outcomes in hepatitis C virus positive donors to hepatitis C virus negative kidney recipients: analysis from National data 2015 [abstract]. *Am J Transplant*. 2015;Suppl. 1:76.

60. Goldberg DS, Abt PL, Blumberg EA, et al. Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. *N Engl J Med*. 2017;376(24):2394-2395.
61. Durand C, Brown D, Wesson R, et al. EXPANDER-1: exploring renal transplants using hepatitis-C infected donors for HCVnegative recipients [abstract 2]. *Am J Transplant*. 2017;17(Suppl. 3):207.
62. Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. *J Am Soc Nephrol*. 2011;22(6):1152-1160.
63. Luan FL, Schaubel DE, Zhang H, et al. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. *Transplantation*. 2008;85(11):1601-1606.
64. Manuel O, Baid-Agrawal S, Moradpour D, Pascual M. Immunosuppression in hepatitis C virus-infected patients after kidney transplantation. *Contrib Nephrol*. 2012;176:97-107.
65. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. *J Am Soc Nephrol*. 2002;13(5):1374-1380.
66. Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. *Transplantation*. 2000;69(5):991-994.
67. Kasuno K, Ono T, Matsumori A, et al. Hepatitis C virus-associated tubulointerstitial injury. *Am J Kidney Dis*. 2003;41(4):767-775.
68. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. *N Engl J Med*. 2012;366(12):1119-1131.
69. Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. *World J Gastroenterol*. 2014;20(24):7544-7554.
70. Sabry A, A EA, Sheashaa H, et al. HCV associated glomerulopathy in Egyptian patients: clinicopathological analysis. *Virology*. 2005;334(1):10-16.
71. Kupin WL. Viral-Associated GN: Hepatitis C and HIV. *Clin J Am Soc Nephrol*. 2017;12(8):1337-1342.
72. Bonacci M, Lens S, Londono MC, et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. *Clin Gastroenterol Hepatol*. 2017;15(4):575-583 e571.
73. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. *Arthritis Rheum*. 2012;64(3):843-853.
74. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. *Arthritis Rheum*. 2012;64(3):835-842.
75. Roccatello D, Sciascia S, Baldovino S, et al. Improved (4 Plus 2) Rituximab Protocol for Severe Cases of Mixed Cryoglobulinemia: A 6-Year Observational Study. *Am J Nephrol*. 2016;43(4):251-260.
76. US Food & Drug Administration. FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). <https://www.fda.gov/Drugs/DrugSafety/ucm366406.htm>. Accessed February 25, 2019.
77. Assefa Y, Hill PS, Williams OD. Access to hepatitis C virus treatment: Lessons from implementation of strategies for increasing access to antiretroviral treatment. *Int J Infect Dis*. 2018;70:65-68.
78. European Union HCVC. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. *Lancet Gastroenterol Hepatol*. 2017;2(5):325-336.
79. Ghinea N, Lipworth W, Day R, Hill A, Dore GJ, Danta M. Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. *Lancet*. 2017;389(10075):1268-1272.

80. The Lancet. Towards elimination of viral hepatitis by 2030. *Lancet*. 2016;388(10042):308.

Legends for Table and Figures


Table 1: Comparison of trials reporting use of DAAs in advanced CKD (G4 and G5, i.e. eGFR < 30 ml/min/1.73 m²) *GT* – Genotype; *EBR/GZR* – Elbasvir/Grazoprevir; *OBV* – Ombitasvir; *PTV/r*- Ritonavir-boosted Paritaprevir; *DSV*- Dasabuvir; *SVR-12*- Sustained viral remission at 12 weeks; *ITT*- Intention to treat; *HD*- Hemodialysis

Study	C-Surfer	Expedition-4	Ruby-II
Design	Multi-center Randomized, Double-blinded Phase-3 trial	Multi-center, Open label, Single-group, Phase-3 trial	Multi-center, Open-label, Phase-3 trial
No. of patients	235	104	18
Treatment naïve	80%	58%	72%
Patients on dialysis	76%	82%	94%
Patients with cirrhosis	6%	19%	0%
HCV Genotypes	GT 1	All GTs, GT 1(52%)	GT 1a (72%), GT 4
Intervention	Immediate treatment with EBR/GZR	Glecaprevir/Pibrentasvir	OBV/PTV/r ± DSV (for GT 1)
Comparison	Deferred treatment group	None	None
Duration of Treatment	12 weeks	12 weeks	12 weeks
Follow-up	16 weeks post-treatment	36 weeks post-treatment	24 weeks post-treatment
SVR-12	99%	98%	94%
ITT analysis	Yes	Yes	Yes
Rate of relapse	1 patient	None	Not reported
Frequency of adverse events	Similar in both groups	Serious adverse events in 24% of patients	Serious adverse events in 5% of patients
Decline in kidney function	2 patients initiated HD, 4 patients had a negative change in CKD stage	No significant change in mean eGFR	17 out of 18 patients were on dialysis at the start of study
Discontinued treatment due to adverse events	None	4 patients	2 patients

Figure 1: Current CKD nomenclature used by KDIGO

				Persistent albuminuria categories, description and range		
				A1	A2	A3
				Normal to mildly increased	Moderately increased	Severely increased
				<30 mg/g <3 mg/mmol	30–300 mg/g 3–30 mg/mmol	>300 mg/g >30 mg/mmol
GFR categories (mL/min/1.73 m ²), description and range	G1	Normal or high	≥90	Low risk	Moderately increased risk	High risk
	G2	Mildly decreased	60–89	Low risk	Moderately increased risk	High risk
	G3a	Mildly to moderately decreased	45–59	Moderately increased risk	High risk	Very high risk
	G3b	Moderately to severely decreased	30–44	High risk	Very high risk	Very high risk
	G4	Severely decreased	15–29	Very high risk	Very high risk	Very high risk
	G5	Kidney failure	<15	Very high risk	Very high risk	Very high risk

Algorithm 1: Treatment scheme for HCV-infected patients with CKD (G1-G5)



Algorithm 2: Proposed scheme for HCV treatment in kidney transplant candidates

